Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Judson

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Cancer Research|December 24, 2011
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancersMounia Beloueche-Babari, Vaitha Arunan, Helen Troy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupL Svancárová, J Y Blay, I R Judson, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumorsDebashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
The Oncologist|March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumorsChooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
British Journal of Cancer|June 4, 2014
Dichloroacetate induces autophagy in colorectal cancer cells and tumoursG Lin, D K Hill, G Andrejeva, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Cancer Research|December 24, 2011
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancersMounia Beloueche-Babari, Vaitha Arunan, Helen Troy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupL Svancárová, J Y Blay, I R Judson, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumorsDebashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
The Oncologist|March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumorsChooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
British Journal of Cancer|June 4, 2014
Dichloroacetate induces autophagy in colorectal cancer cells and tumoursG Lin, D K Hill, G Andrejeva, et al.
Pageof 14